EGFR and non-small cell lung carcinoma: However, randomized chemotherapy plus an anti-EGFR-mAb did not reduce the risk of death in patients with non-squamous NSCLC compared with chemotherapy alone (HR = 1.01, 95%CI: 0.84-1.21, P = .92) (Fig. 3A).